65,437 trials
HIV-1 Infection
Primary: Virological Response[Viral Load <50 Copies/mL, TLOVR] — 11; 1 Participants
Acute Gout
Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days
Dermatitis, Contact
Primary: Treatment Status (Success/Failure) of Contact Dermatitis (CD) at the Second Follow-up Visit — 93.8; 6.30 Percentage of Participants
Tachycardia
Primary: Number of Patients With Inappropriate Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) Therapy (Shock or Antitachycardia Pacing [ATP]) After the Pre-Discharge…
High Altitude Headache
Primary: Change in Optic Nerve Sheath Diameter by Ultrasonography — 0.02; 0.02 mm — p=0.98
Non Small Cell Lung Cancer
Primary: Progression Free Survival During Maintenance Phase — 3.2; 3.2 months — p=0.1815
Benign Prostatic Hyperplasia (BPH)
Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks — -4.2; -6.3; -5.7 units on a scale — p=0.001
Chronic Kidney Disease
Primary: Muscle Cross Sectional Area — 3.24; -4.62; 4.39; -0.15 cm2 — p=0.30
Chronic Kidney Disease · Left Ventricular Hypertrophy
Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI) — 0.34; -0.07 grams/meter^2.7 — p=0.145
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Hilar Cholangiocarcinoma
Primary: Proportion of Patients With Adequate Biliary Drainage in Metallic Stent and Plastic Stent Group.(ITT Analysis) — .7037037; .46296 proportion of participants — p=0.011
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
Insomnia
Primary: Area Under the Concentration-Time Curve (AUC) for LY2624803 and the Metabolite LSN2797276 — 5240; 3340; 4620; 192 nanogram*hour per milliliter (ng*h/mL)
Head and Neck Neoplasms
Primary: Adverse Events — 4; 4; 5; 4 participants
Malignant Melanoma
Primary: Best Overall Response (BOR) Assessed by an Independent Review Committee Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 52.3 Percentage of participants